- Collaboration provides support for platform and funding to support development of safer, more-specific ADCs on up to three cancer targets - SAN FRANCISCO, Sept. 23, 2025 /PRNewswire/ -- TegMine ...

– Collaboration provides support for platform and funding to support development of safer, more-specific ADCs on up to three cancer targets – SAN FRANCISCO, Sept. 23, 2025 /PRNewswire/ — TegMine ...

Abstract: In this article, a new multioutput switched-capacitor multilevel inverter (SCMLI) and a few trade-off solutions are proposed. It concomitantly features a common input source-load ground, ...

In this valuable study, the authors aimed to identify and characterize intrinsic factors that govern the aging process of bone marrow mesenchymal stromal cells (BMSCs), which are believed to be ...

Background: A 33 year old woman presented with chronic fatigue. Her symptoms seemed to begin after cessation of breastfeeding her child. She had been diagnosed with hypothyroidism and prescribed ...

Interim findings showed, the estimated mean annualized bleeding rate for treated bleeds was 0.53, with a median ABR of 0. Topline results were announced from a phase 3 trial evaluating Mim8 in ...

DEAR DR. ROACH: I am 71 years old and was diagnosed with pernicious anemia in October 2024. My B12 and folate levels were low. My antiparietal antibodies were abnormal, but the intrinsic factor ...

DEAR DR. ROACH: I am 71 years old and was diagnosed with pernicious anemia in October 2024. My B12 and folate levels were low. My antiparietal antibodies were abnormal, but the intrinsic factor ...

TARRYTOWN, N.Y., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct ...

ABSTRACT: Megaloblastic pernicious anemia is an autoimmune disorder, considered rare in African context. The objective of this study was to report four clinical cases collected at the CHUR/OHG, and to ...